Antonio Jirillo - Concepedia

Author

Antonio Jirillo

Istituto Oncologico Veneto

Also Known As

A JIRILLO, A Jirillo, A. Jirillo, A. Jirillo⁎, Antonio Jirillo, R Demicheli

110

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Istituto Oncologico Veneto Istituti di Ricovero e Cura a Carattere Scientifico University of Padua University of Verona Azienda Ospedale - Università Padova

About

Antonio Jirillo is an author at Istituto Oncologico Veneto specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	15	881
2	Health Sciences	3	3	618
3	Nursing	2	2	29
4	Public Health	1	1	15
5	Family Medicine	1	1	14

Antonio Jirillo

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Phase III Trial of Initial Chemotherapy in Stage III or IV Head and Neck Cancers: a Study by the Gruppo di Studio sui Tumori della Testa e del Collo Adriano Paccagnella, Antonio Orlando, C. Marchiori, JNCI Journal of the National Cancer Institute	1994	420
Randomized Phase III Trial of Neoadjuvant Chemotherapy in Head and Neck Cancer: 10-Year Follow-Up P. L. Zorat, A. Paccagnella, G Cavaniglia, JNCI Journal of the National Cancer Institute	2004	186
M30 Neoepitope Expression in Epithelial Cancer: Quantification of Apoptosis in Circulating Tumor Cells by CellSearch Analysis Elisabetta Rossi, Umberto Basso, Romina Celadin, Clinical Cancer Research	2010	128
Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer Elisabetta Rossi, Matteo Fassan, Michele Aieta, British Journal of Cancer	2012	60
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial Lucia Del Mastro, Francesca Poggio, Eva Blondeaux, The Lancet Oncology End-of-study ResultsBreast OncologyEarly-stage Breast CancerMedicineBreast Cancer	2022	46
Adjuvant chemotherapy for elderly patients (≥70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients Antonella Brunello, Umberto Basso, C. Pogliani, Annals of Oncology Geriatric OncologySurgical OncologyBreast OncologyElderly PatientsGeriatrics	2005	43
Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study Alba A. Brandes, Umberto Basso, Francesca Vastola, Annals of Oncology Neuro-oncologyRecurrent OligodendrogliomaGliomaMedicineMetronomic Therapy	2003	40
A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer Sara Cresta, Giacomo Grasselli, Mauro Mansutti, Annals of Oncology	2004	38
FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases. Lara Maria Pasetto, Antonio Jirillo, Girolama Iadicicco, PubMed	2005	38

Page 1